Other ATR inhibitors, schisandrin B [135,136,137] and KU60019 [138,139], presented promising anti-tumor properties in vitro and partly in vivo in luminal A breast cancer models, however, they have a limited clinical use due to a poor bioavailability. This evidence concerns the gene ATR and breast cancer.